
Hims & Hers Health today introduced MedMatch, a technology designed to give providers a more intelligent and informed way to deliver personalized care to patients with more effective and precise treatments and medications.
Currently in Beta, MedMatch deploys artificial intelligence and machine learning against the expansive dataset at the core of the Hims & Hers platform. Leveraging millions of anonymized data points from millions of customers, MedMatch models can identify treatments in real-time that may be best suited for a patient’s unique needs. The company is initially deploying MedMatch for customers seeking support for anxiety and depression on the Hims & Hers platform.
MedMatch is being developed to help providers on the platform identify the optimal treatment for a particular person, which can include the most appropriate treatment formulation to dosage strength to form factor. Trained on anonymized historical clinical visits, demographics, treatment types, and patient outcomes, MedMatch is being built to have the unique ability to recommend clinical decisions and treatments supported and informed by the collective knowledge of thousands of providers and millions of data points. We believe connecting the patient with the right personalized treatment will result in better clinical outcomes, leading to long-term patient happiness.
In this initial Beta phase, MedMatch is being evaluated on independent metrics including remission rates once treatment begins, time to remission, and patient satisfaction.
As development of the MedMatch model continues, we plan to add more robust capabilities and expand the model to additional health categories on the Hims & Hers platform to progress towards the ability to deliver this unprecedented standard of personalized care to patients across a range of healthcare conditions. Stay tuned for further developments and updates of this exciting new technology in the months to come.